Literature DB >> 3940638

Retardation of tumor growth in mice caused by radiation-induced injury of tumor bed stroma: dependency on tumor type.

L Milas, H Ito, N Hunter, S Jones, L J Peters.   

Abstract

Dependency on tumor type of tumor growth retardation caused by the radiation-induced damage of tumor bed stroma, a phenomenon known as the tumor bed effect (TBE), was investigated using two mammary carcinomas designated MCA-4 and MCA-K and two fibrosarcomas designated FSA and NFSA, all syngeneic to C3Hf/Kam mice. Inoculations of tumor cells were given s.c. into the right hind thighs of mice either treated or not treated 1 day earlier with graded doses of gamma-rays; tumor latency and growth rate were determined. Tumor latency was prolonged and tumor growth was retarded, but the magnitude of these two features of TBE greatly depended on radiation dose and tumor type. TBE began to appear at doses of 5-10 Gy and then sharply increased as the dose of radiation was increased up to between 20 and 30 Gy, at which point a plateau was achieved. TBE was also significant after 40 and 60 Gy total dose given in daily fractions of 2 Gy 5 times per week, a schedule commonly used in radiotherapy treatment of cancer patients. Carcinomas exhibited more pronounced TBE than fibrosarcomas, with NFSA showing only minimal TBE. Radiation-inactivated MCA-4 and FSA cells admixed with viable MCA-4 cells reduced tumor latency, but not the tumor growth delay, of resulting MCA-4 tumors in preirradiated legs. In contrast, admixture of irradiated NFSA and viable MCA-4 cells abolished growth delay but did not influence tumor latency of the TBE phenomenon. Thus the type of a tumor growing in the irradiated tissue is a very important factor that determines the expression of TBE.

Entities:  

Mesh:

Year:  1986        PMID: 3940638

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival.

Authors:  Wendy A Woodward; Pauline T Truong; Tse-Kuan Yu; Welela Tereffe; Julia Oh; George Perkins; Eric Strom; Funda Meric-Bernstam; Ana-Maria Gonzalez-Angulo; Caroline Speers; Joseph Ragaz; Thomas A Buchholz
Journal:  Breast Cancer Res Treat       Date:  2010-03-20       Impact factor: 4.872

Review 2.  Are cancer stem cells radioresistant?

Authors:  Walter N Hittelman; Yong Liao; Li Wang; Luka Milas
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

3.  The role of salvage reirradiation for malignant gliomas that progress on bevacizumab.

Authors:  Roy G Torcuator; Ravneet Thind; Mehul Patel; Y S Mohan; Joseph Anderson; Thomas Doyle; Samuel Ryu; Rajan Jain; Lonni Schultz; Mark Rosenblum; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2009-10-17       Impact factor: 4.130

4.  Autocrine and paracrine growth factors in tumor growth: a mathematical model.

Authors:  S Michelson; J Leith
Journal:  Bull Math Biol       Date:  1991       Impact factor: 1.758

Review 5.  Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cell Cycle       Date:  2009-04-04       Impact factor: 4.534

6.  Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

7.  Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.

Authors:  Philip H Gutin; Fabio M Iwamoto; Kathryn Beal; Nimish A Mohile; Sasan Karimi; Bob L Hou; Stella Lymberis; Yoshiya Yamada; Jenghwa Chang; Lauren E Abrey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-01-23       Impact factor: 7.038

8.  Competitive exclusion of clonal subpopulations in heterogeneous tumours after stromal injury.

Authors:  J T Leith; S Michelson; A S Glicksman
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

9.  Enhanced radiosensitizing by sodium glycididazole in a recurrent esophageal carcinoma tumor model.

Authors:  Peipei Wu; Jing Liu; Xiaorong Sun; Xiaolin Li; Ligang Xing; Jinming Yu
Journal:  Oncotarget       Date:  2017-07-10

10.  Generation of bone marrow chimeras using X-ray irradiation: comparison to cesium irradiation and use in immunotherapy.

Authors:  Jason Eng; Jessica Orf; Kristy Perez; Deepali Sawant; Jason DeVoss
Journal:  J Biol Methods       Date:  2020-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.